Staidson (Beijing) Biopharmaceuticals Co Ltd operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Staidson (Beijing) Biopharmaceuticals Co Ltd with three other
companies in this sector in China:
Jiangxi Boya Bio-Pharmaceutical Co Ltd
sales of 946.57 million Chinese Renmimbi [US$137.44 million]
of which 56%
was Blood Plasma),
Chongqing Zhifei Biological Products Co Ltd
(445.92 million Chinese Renmimbi [US$64.75 million]
of which 99%
was Biological Product), and
China Biologic Products, Inc.
(2.27 billion Chinese Renmimbi [US$329.59 million]
of which 100%
was Human Blood Product).
Staidson (Beijing) Biopharmaceuticals Co Ltd reported sales of 1.40 billion Chinese Renmimbi (US$203.76 million)
December of 2016.
increase of 12.5%
versus 2015, when the company's sales were 1.25 billion Chinese Renmimbi.
Sales at Staidson (Beijing) Biopharmaceuticals Co Ltd have increased during each of the previous five years
(and since 2011, sales have increased a total of 582%).